Volume 14 Supplement 5
B cells in autoimmune diseases: Part 1
The supplement was proposed by the journal and content was developed in consultation with the Editor-in-Chief. Articles have been independently prepared by the authors and have undergone the journal's standard peer review process. Publication of the supplement was supported by Medimmune.
This supplement has been published in two parts. Part 2 is available at http://arthritis-research.com/supplements/15/S1.
Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides and h...
Arthritis Research & Therapy 2012 14(Suppl 5):S1
Published on: 8 November 2012